Renaissance Washington, DC Downtown Hotel
Renaissance Ballroom (Ballroom Level)
999 Ninth Street NW
Washington, DC 20001
6:30 PM Registration and Dinner
7:00 PM Introduction: Setting the Stage For an Exploration of Immunotherapy in Solid Tumors
(Naiyer Rizvi, MD)
7:10 PM Foundational Evidence on Checkpoint Blockade in Cancer Care
(Edward B. Garon, MD, MS)
7:35 PM Bench to Bedside: Novel Immune Therapy Combinations in Solid Tumors
(Geoffrey T. Gibney, MD)
8:00 PM Assessing Progress in the Advancement of Cancer Immunotherapy Biomarkers
(David L. Rimm, MD, PhD)
8:25 PM How I Use Immunotherapy in Everyday Practice—A Personal Look at Harnessing the Immune System Against Cancer
(Naiyer Rizvi, MD)
8:50 PM Summing Up Cancer Immunotherapy and Audience Q&A
The emergence and validation of immunotherapy via checkpoint blockade has represented a leap forward in medical care, and has offered patients and clinicians a new weapon—via anticancer immune stimulation—in the fight against multiple solid tumors. These powerful immune approaches have changed the way clinicians manage patients with diseases such as melanoma and lung cancer, while recently making inroads into disorders as different as bladder and head and neck cancer. But what does the future hold? Will novel immune-based combination therapy make older standards of care irrelevant? Has there been progress in validating biomarkers for immunotherapy? And what does all this mean for everyday practice?
If you are interested in the answers to these questions, and are curious how experts are navigating the fluid world of cancer immunotherapy, join a panel of oncology experts at PeerView’s latest live event, held during the annual cancer research meeting in April 2017--and get an inside look at how targeting the immune system in cancer will change the way you fight cancer.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of oncologists, cancer research scientists, and other clinicians involved in the management of patients with cancer.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.
Release and Expiration Dates: April 1, 2017
Time to Complete: 120 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.
Naiyer Rizvi, MD
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York
Geoffrey T. Gibney, MD
Co-Leader, Melanoma Disease Group
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Edward B. Garon, MD, MS
Health Sciences Associate Professor
Department of Medicine, Division of Hematology-Oncology
UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California
David L. Rimm, MD, PhD
Professor of Pathology and Medicine (Medical Oncology)
Director, Yale Pathology Tissue Services
Yale University School of Medicine
New Haven, Connecticut
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by educational grants from Genentech, Incyte Corporation, and Merck & Co., Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.